- Porter's Daily Journal
- Posts
- When High Convictions Run Against The Herd
When High Convictions Run Against The Herd
Porter's Journal Issue #136, Volume #2
Porter Stansberry
November 24, 2025
The Newest Member Of The $1T Club… Pharma Giant Eli Lilly
This is Porter’s Daily Journal, a free e-letter from Porter & Co. that provides unfiltered insights on markets, the economy, and life to help readers become better investors. It includes weekday editions and two weekend editions… and is free to all subscribers.
Editor’s note: Because of the holiday week ahead, we will next publish Porter’s Daily Journal on Monday, December 1 – to give staff and readers time to spend time with family and friends. All of us here at Porter & Co. wish you all a Happy (and tasty) Thanksgiving.
The trillion-dollar club… Sticking with convictions… Facts first, emotions never… A top-performing Best Buy… A rare entry into High Conviction… Complete Investor’s big weekend… DOGE, RIP… |
Table of Contents
Eli Lilly (NYSE: LLY) has joined the $1 trillion club – bringing it into the elite group of companies that have stamped nine zeroes onto their market cap… the first in healthcare to do so.
In June, we recommended shares of the pharmaceutical giant in Complete Investor (still called The Big Secret On Wall Street at the time) at $795 – and they are now up 35%. But it was not a straight path up.
We like Eli Lilly because it is a global leader in the explosive GLP-1 diabetes and weight-loss market. But in August, just weeks after our recommendation, the stock fell 20% after an early setback in the trial for its disruptive weight-loss GLP-1 pill, Orforglipron. That market panic created a rare opportunity to buy a forever stock, whose fundamentals remained rock solid, at a relative valuation low.
Heading into Eli Lilly’s August 7 Q2 earnings call, investors were expecting weight-loss results of at least 15% in its latest Food And Drug Administration (“FDA”) trial. Instead, the FDA’s Phase III data showed 12.4% average weight loss over 72 weeks at the highest dose – a small difference that sparked a big 20% sell-off. But instead of selling along with the market, we leaned in and made Eli Lilly one of our three August Best Buys – the companies among all in the portfolio that are at the most attractive buy point. The results were perfectly solid, we said:
Despite the setback, we believe this is a significant overreaction. Eli Lilly plans to continue moving the drug through its development pipeline, with a launch planned next year, pending regulatory approval.”